Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9623
Peer-review started: May 8, 2016
First decision: June 20, 2016
Revised: July 11, 2016
Accepted: July 31, 2016
Article in press: August 1, 2016
Published online: November 21, 2016
Processing time: 195 Days and 18.5 Hours
To determine the outcomes of partial splenic embolization (PSE) for massive splenomegaly due to idiopathic portal hypertension (IPH).
In this prospective study, we evaluated the characteristics and prognosis of consecutive patients with IPH who underwent PSE for all indications at a single medical center between June 2009 and January 2015. The inclusion criteria were: presence of hypersplenism, massive splenomegaly, and resultant pancytopenia. The exclusion criteria were: presence of other diseases causing portal hypertension. During the post-PSE period, the patients were hospitalized. All patients underwent abdominal computed tomography imaging 4 wk post-PSE to determine total splenic and non-infarcted splenic volumes.
A total of 11 patients, with median age of 33.27 ± 4.8 years, were included in the study. Mean spleen size was 22.9 cm (21-28 cm), and severe hypersplenism was diagnosed in all patients before PSE. Post-PSE, leukocyte and platelet counts increased significantly, reaching peak levels in the second week with gradual decreases thereafter. Liver function tests did not exhibit significant changes during post-intervention follow-up. All patients developed post-embolization syndrome, and one patient experienced serious complications; all complications were successfully treated with conservative therapy and no death occurred.
Our findings showed that PSE has a lower complication rate than previously-reported surgical complication rates, which supports this intervention as a viable alternative for high-risk operable patients with severe hypersplenism.
Core tip: Partial splenic embolization (PSE) for hypersplenism is a novel percutaneous interventional method, has emerged as an alternative to surgery and is a viable approach in high-risk and inoperable patients with portal hypertension. The current trial, which is the largest study in the current literature, confirmed the safety and efficacy of PSE in patients with idiopathic portal hypertension (IPH) regarding complications and morbidity. PSE could be offered to patients with massive splenomegaly due to IPH, with low and manageable complication rates, as this study has confirmed.